Disease · MONDO_0016093

borderline epithelial tumor of ovary

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. borderline epithelial tumor of ovary. Diseases, record MONDO_0016093. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016093

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: borderline epithelial tumor of ovary; Open Targets
Open Targets ID: MONDO_0016093; Open Targets
Other names: borderline epithelial neoplasm of ovary, borderline epithelial neoplasm of the ovary, borderline epithelial tumor of the ovary, borderline epithelial tumour of the ovary, borderline ovarian epithelial neoplasm, borderline ovarian epithelial tumor, borderline ovarian epithelial tumour, borderline ovarian surface epithelial-stromal tumor, borderline ovarian surface epithelial-stromal tumour, epithelial neoplasm of ovary of borderline malignancy, epithelial neoplasm of the ovary of borderline malignancy, epithelial ovarian neoplasm of borderline malignancy, epithelial ovarian tumor of borderline malignancy, epithelial ovarian tumour of borderline malignancy, epithelial tumor of ovary of borderline malignancy, epithelial tumor of the ovary of borderline malignancy, epithelial tumour of ovary of borderline malignancy, epithelial tumour of the ovary of borderline malignancy, low malignant potential ovarian tumor, low malignant potential ovarian tumour, ovarian borderline malignant tumor, ovarian borderline malignant tumour, ovarian low malignant potential tumor, ovarian low malignant potential tumour, ovarian tum. of low malig. poten., ovarian tumor of low malignant potential, ovarian tumors of low malignant potential, ovarian tumour of low malignant potential, ovarian tumours of low malignant potential; Open Targets
NCI Thesaurus: C4783; NCI Thesaurus
Orphanet: ORPHA:206473; Orphanet
Highest stage of its drugs: Phase 2, for 2 of its 2 drugs, from ClinicalTrials.gov; Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BELINOSTAT	CHEMBL408513	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets15

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
HDAC1	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC10	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC2	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC4	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/9759	Drugs and targets
HDAC5	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10014	Drugs and targets
HDAC6	Histone deacetylase	1	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets

1 to 10 of 15

See all 15 targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00301756	Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors	Phase 2	32	2016-12-14	Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Ovarian Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Ovarian Cancer	BELINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT00039585	Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor	Phase 2			Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016093

GET https://conductscience.org/api/diseases/v1/MONDO_0016093/drugs

API reference For AI assistants